Skip to content

    Cohance Lifesciences Limited

    COHANCEGood
    Healthcare·13 Aug 2025
    Management Summary

    Cohance Lifesciences delivered a resilient Q1 FY26, marking its first full quarter as a unified platform. While reported CDMO growth was muted by inventory de-stocking in two large commercial molecules, the underlying business showed robust momentum, particularly in niche modalities like ADCs and Oligonucleotides. Management is aggressively investing in global capacity and leadership to hit its ambitious 2030 growth targets.

    Highlights

    7

    • Reported revenue growth of 13% YoY, driven by Specialty Chemicals and API segments.

    • Pharma CDMO segment grew over 30% YoY when excluding the temporary impact of inventory de-stocking.

    • Niche technology revenue share (ADCs, Oligos) increased to over 20% in Q1 FY26, up from mid-teens in FY25.

    • Generated strong free cash flow of ₹230 crores (INR 2.3 billion) with a closing cash balance of ₹440 crores (INR 4.4 billion).

    • Committed $10 million investment for a dedicated CGMP bioconjugation suite at the Princeton facility (NJ Bio).

    • Nacharam Oligonucleotide facility (₹23 crore investment) is on track to be fully operational by end of CY 2025.

    • Reiterated long-term guidance of reaching $1 billion (₹8,500 crores) revenue by 2030 with mid-30s EBITDA margins.

    Concerns

    1

    • Inventory De-stocking

    What Changed1

    vs Q2 FY26

    Guidance items3 → 5 (+2)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue Growth13%+13%YoY
    2. 02Free Cash Flow₹230 Cr
    3. 03Cash Balance₹440 Cr
    4. 04CAPEX₹55.9 Cr
    5. 05Niche Tech Revenue Share20%

    Segment breakdown

    Pharma CDMO
    100% Reported Revenue Growth30% Adjusted Revenue Growth
    API Plus
    90% Revenue Growth
    Specialty Chemicals
    28% Revenue Growth
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Total Revenue
    $1 billion (₹85 billion)
    		High
    Revenue
    Niche Technology Revenue Share
    mid-20s
    		High
    Margin
    EBITDA Margin
    mid-30s
    		Medium
    Capacity
    Oligonucleotide Facility Operationality
    Fully operational
    		High
    Other
    API Product Validations
    7 to 8
    		High

    Risks & concerns

    5
    RiskSeverity

    Inventory De-stocking

    Two large commercial molecules are currently undergoing de-stocking, which significantly muted reported Pharma CDMO growth in Q1. — Management acknowledged

    high

    One-time M&A and ESOP Expenses

    Significant non-operating expenses related to talent acquisition, legal services for M&A, and ESOP charges are impacting EBITDA margins. — Analyst acknowledged

    medium

    Geopolitical/Tariff Risks

    Management believes Pharma is largely exempt and their FOB contract terms protect them from direct liability. — Both downplayed

    low

    Areas of Evasion(2)

    • Specific organic growth percentage for FY26
    • Detailed breakdown of the $660m revenue gap to 2030

    Q&A highlights

    3

    “For us, the organic and inorganic are two sides of the same coin. It is about capital allocation... I would urge you guys to kind of think about it in the way we look at and not separating it as an organic or inorganic.”

    Management declined to provide a specific organic growth target for the current fiscal year, focusing instead on their M&A-led strategy.

    asked by Shyam Srinivasan

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Pivot to Niche Modalities

    Cohance is aggressively positioning itself in high-value, complex modalities such as Antibody-Drug Conjugates (ADCs) and Oligonucleotides. The niche technology segment already accounts for over 20% of revenue and is growing faster than the core CDMO business. The $10 million investment in NJ Bio's Princeton facility and the ₹23 crore investment in the Nacharam Oligo suite are critical steps to capture the 'China Plus One' and 'EU Plus One' diversification trends.

    02

    Inventory De-stocking Masks Underlying Growth

    The reported 1% growth in Pharma CDMO is deceptive due to inventory de-stocking in two major commercial molecules. Management highlighted that excluding this impact, the segment grew by over 30% YoY. This de-stocking is described as a 'year phenomenon,' suggesting that while it may persist in the near term, the underlying demand from innovator partners remains robust.

    03

    Financial Discipline and Capital Allocation

    The company maintains a strong balance sheet with ₹440 crores in cash and generated ₹230 crores in free cash flow during the quarter. Management views organic and inorganic growth as interchangeable tools for capital allocation, signaling a continued appetite for value-accretive acquisitions to add capabilities or geographical presence.

    04

    Global Expansion and Leadership Strengthening

    Cohance is expanding its front-end capabilities in the US, Europe, and Japan, recently adding experienced CDMO professionals and forming an External Advisory Board of industry stalwarts. The appointment of Yann D’Herve as CEO of the CDMO business, bringing 30 years of experience, is a strategic move to align the organization with its $1 billion global ambition.

    05

    API Plus and Specialty Chemicals Recovery

    The API Plus segment delivered a standout 90% growth, driven by a focus on matured products with cost leadership and lifecycle management for innovators. Meanwhile, the Specialty Chemicals segment is seeing a sequential recovery in AgChem, with Performance Chemicals expected to ramp up significantly in the second half of the fiscal year.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.